Clik here to view.
100%-Owned Subsidiary, Health House International Generates Quarterly Net...
Melodiol Global Health Limited (ASX:ME1, FRA:1X8) (‘Melodiol’ or ‘the Company’) is pleased to provide the following trading update for the Australian division of its fully-owned subsidiary, Health...
View ArticleClik here to view.
Seelos Therapeutics Retains Canaccord Genuity in Connection with Review of...
Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today...
View ArticleClik here to view.
Melodiol Delivers Another Record Quarter with ~$7.5M in Revenue Generated...
Melodiol Global Health Limited (ASX:ME1, FRA:1X8) (‘Melodiol’ or ‘the Company’) is pleased to advise that it has achieved another record quarter of growth, delivering ~$7,497,891 in unaudited net...
View ArticleClik here to view.
Bonus Issue of Options and Other Corporate Updates
Melodiol Global Health Limited (ASX:ME1, FRA:1X8) (‘Melodiol’ or ‘the Company’) is pleased to announce a pro- rata non-renounceable bonus issue of options to eligible shareholders on the basis of one...
View ArticleClik here to view.
Melodiol Global Health Limited (ASX: ME1) – Trading Halt
DescriptionThe securities of Melodiol Global Health Limited (‘ME1’) will be placed in trading halt at the request of ME1, pending it releasing an announcement. Unless ASX decides otherwise, the...
View ArticleClik here to view.
Capital Raising & Corporate Update
Melodiol Global Health Limited (ASX:ME1) (‘Melodiol’ or ‘the Company’) is pleased to advise it has received firm commitments to raise approximately $1m (before costs) through the issue of...
View ArticleClik here to view.
COMPASS Pathways announces CFO transition
COMPASS Pathways plc (Nasdaq: CMPS) ("COMPASS" or the "company"), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that...
View ArticleTSX Venture Exchange Stock Maintenance Bulletins
TSX VENTURE COMPANIES FLUROTECH LTD. ("TEST.H") [formerly FluroTech Ltd. ("TEST")] BULLETIN TYPE: Transfer and New Addition to NEX, Symbol Change, Resume Trading BULLETIN DATE: October 26, 2023 TSX...
View ArticleClik here to view.
Seelos Therapeutics to Present a Poster on SLS-005 in Alzheimer's Disease at...
-SLS-005 induces autophagy to reduce mutant protein aggregates, and is currently being studied in Alzheimer's disease, Huntington's disease, Amyotrophic Lateral Sclerosis and Spinocerebellar ataxia...
View ArticleClik here to view.
Goodness Growth Holdings Amends Lease Agreement in the State of New York
Goodness Growth Holdings, Inc. ("Goodness Growth" or the "Company") (CSE: GDNS; OTCQX: GDNSF), a cannabis company committed to providing safe access, quality products and great value to its customers,...
View ArticleClik here to view.
Quarterly Activities Report: Another Consecutive Quarter of Record Revenues
Melodiol Global Health Limited (ASX:ME1) (‘Melodiol’ or ‘the Company’) is pleased to provide the following update on progress for the three month period ended 30 September 2023 (the ‘quarter’), as...
View ArticleClik here to view.
COMPASS Pathways Announces Third Quarter 2023 Financial Results and Business...
Highlights: COMP360 Phase 3 pivotal program ongoing with expanding European clinical sites Secured up to $285 million private placement financing with $125 million upfront Cash position at September...
View ArticleClik here to view.
Goodness Growth Holdings to Release Third Quarter 2023 Results on November...
Goodness Growth Holdings, Inc. ("Goodness Growth" or the "Company") (CSE: GDNS; OTCQX: GDNSF), a cannabis company committed to providing safe access, quality products and great value to its customers,...
View ArticleClik here to view.
Melodiol Global Health Limited (ASX: ME1) – Trading Halt
DescriptionThe securities of Melodiol Global Health Limited (‘ME1’) will be placed in trading halt at the request of ME1, pending it releasing an announcement. Unless ASX decides otherwise, the...
View ArticleClik here to view.
Capital Raising Re-Price & Prospectus Offers Extension
Melodiol Global Health Limited (ASX:ME1) (‘Melodiol’ or ‘the Company’) provides an update to its previously announced capital raise and debt conversions (refer to ASX announcement dated 26 October...
View ArticleClik here to view.
Goodness Growth Holdings Announces Third Quarter 2023 Results
Q3 revenue of $24.7 million increased 44.0% YoY and 28.2% sequentially excluding discontinued operations – – Stronger revenue growth and margins largely driven by adult-use activation in Maryland – –...
View ArticleClik here to view.
Compass Pathways initiates UK component of global phase 3 study of psilocybin...
UK sites to participate in part of pivotal phase 3 program following Medicines and Healthcare Regulatory Agency approval of study Research will take place in the UK, including at the newly opened...
View ArticleClik here to view.
Eminent Healthcare Leader Appointed as Independent Non-Executive Chairman for...
Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) focused on developing innovative treatments for mental health and neurological conditions, is pleased to announce the appointment of Greg...
View ArticleClik here to view.
Compass Pathways to participate in upcoming Evercore investor conference
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will hold a...
View ArticleClik here to view.
Seelos Therapeutics Announces 1-for-30 Reverse Stock Split
Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare...
View Article